share_log

The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation

The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation

每日生物技術脈搏:輝瑞-BioNTech 的 COVID-19 兒童版 Booster 即將上市,Ultragenyx 批准了遺傳性疾病基因療法,Ampio 的 AP-013 試驗正在獨立調查中
Benzinga Real-time News ·  2022/05/17 09:09
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是過去24小時生物技術領域的熱門發展綜述:
Stocks In Focus
關注的股票
FDA May Authorize Pfizer-BioNTech's COVID-19 Booster For 5-11 Year Kids Soon: NYT
美國食品和藥物管理局可能很快批准輝瑞-生物科技的新冠肺炎助推器用於5-11歲兒童:紐約時報
The FDA is expected to authorize a booster shot of Pfizer Inc (NYSE:PFE)/BioNTech SE's (NASDAQ:BNTX) COVID-19 vaccine for children ages 5 to 11, likely Tuesday, the New York Times reported, citing people familiar with the matter.
美國食品和藥物管理局預計將授權加強注射。輝瑞(紐約證券交易所市場代碼:PFE)/BioNTech SE‘s紐約時報援引知情人士的話報道,中國(納斯達克代碼:BNTX)為5歲至11歲的兒童接種新冠肺炎疫苗,可能會在週二。
It is unclear how much demand there is for the third dose in the age group. According to the U.S. Centers for Disease Control and Prevention, just 28.8% of children ages...
目前尚不清楚該年齡段的第三劑疫苗的需求量有多大。根據美國疾病控...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論